Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 2/20 | 0.40 |
| ▸ | RARG | P13631 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538229 | 0.88 | TDP1 (0.44) | TDP1SMN1; SMN2PTPN1NPC1RAB9A | |
| SCHEMBL1838535 | 0.85 | SMN1; SMN2 (0.46) | TDP1SMN1; SMN2PTPN1NPC1RAB9A | |
| SCHEMBL262785 | 0.85 | HTT (0.51) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL263653 | 0.84 | TDP1 (0.53) | TDP1SMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL538271 | 0.84 | SMN1; SMN2 (0.51) | TDP1SMN1; SMN2PTPN1NPC1RAB9A | |
| SCHEMBL29518583 | 0.84 | SMN1; SMN2 (0.51) | TDP1SMN1; SMN2PTPN1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL998884 | 0.83 | SMN1; SMN2 (0.50) | TDP1SMN1; SMN2PTPN1NPC1RAB9A | |
| SCHEMBL264392 | 0.77 | BACE1 (0.46) | MAPTHSD11B1 | |
| SCHEMBL263313 | 0.77 | PTPN1 (0.59) | PTPN1KDM4EPDK1PDK2PDK3 | |
| SCHEMBL1842933 | 0.77 | PTPN1 (0.59) | PTPN1KDM4EPDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-7964732-B2 | Substituted bicyclocarboxyamide compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964732-B2 | Substituted bicyclocarboxyamide compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964732-B2 | Substituted bicyclocarboxyamide compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2091944-B1 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2091944-B1 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | Pfizer, Inc. and Renovis Inc. | 2010-10-21 | — | — | US | disclosed |
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | Pfizer, Inc. and Renovis Inc. | 2010-10-21 | — | — | US | disclosed |
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | Pfizer, Inc. and Renovis Inc. | 2010-10-21 | — | — | US | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| EP-2044018-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | Pfizer Japan, Inc. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008059370-A2 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008007211-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | TRPV1, OPRL1, CNR1 | TDP1 2962/4885SMN1; SMN2 1328/4885PTPN1 3332/4885 |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | OPRL1, CNR1, TRPV1 | TDP1 3439/4885SMN1; SMN2 1166/4885PTPN1 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.